Sublingual Administration
Articles & Whitepapers
-
Project - Sublingual Semaglutide
Semaglutide is currently the only GLP-1 product available as an oral product. Biolingus aims at developing a sublingual version of this product. This should have a substantially lower COGS and hence competitive with the oral ...
-
Project - Sublingual insulin+ (fixed dose combination product of insulin and exenatide/liraglutide)
The global human insulin market is projected to surpass USD 40 Billion USD. Our sublingual “insulin+” product will be positioned in a particular segment of this market : it will be ...
News
-
BioLingus to Develop a Sublingual Vaccine for COVID in Cooperation With the Korean CHA Vaccine Institute and PanGen Biotech
Biolingus IP II GmbH and the CHA Vaccine Institute Co., Ltd., with support from the Korean biotech company PanGen Biotech Inc., will collaborate to develop a sublingual vaccine for COVID. The project has received research funding from The Research ...
Alex Huybens appointed as Chief Executive Officer (CEO) of HAL Allergy Holding B.V. and HALIX B.V.
Allovate Therapeutics Appoints Bob Pomrenke as CEO
HAL Allergy first company to achieve marketing authorisations in line with Therapieallergene-Verordnung (TAV) in Germany
Allovate Therapeutics Announces Issuance of U.S. Patent Covering Novel Oral Mucosal Immunotherapy Platform
Equipment & Solutions
-
Showcase
THC Oral/Sublingual Strip
Clinical studies are planned in 2021 to demonstrate the efficient sublingual delivery of THC for anorexia and nausea.